Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Coronary Artery Disease IV: Preventive Measures01:26

Coronary Artery Disease IV: Preventive Measures

741
Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...
741
Imaging Studies for Cardiovascular System VI: Calcium -Scoring CT01:25

Imaging Studies for Cardiovascular System VI: Calcium -Scoring CT

545
Calcium-Scoring CT ScanA calcium-scoring CT scan, also known as coronary artery calcium (CAC) scan, detects calcium deposits in the coronary arteries. This test assesses the risk of coronary artery disease (CAD), which can lead to cardiovascular events such as angina, heart failure, and sudden cardiac arrest.A calcium-scoring CT scan is generally recommended for individuals at intermediate risk of CAD without symptoms. It includes:Men aged 40-75 and women aged 50-75: Especially those with a...
545
Coronary Artery Disease I: Introduction01:30

Coronary Artery Disease I: Introduction

1.2K
Coronary Artery Disease (CAD): An Overview with Scientific InsightsCoronary Artery Disease (CAD), often referred to as C-A-D, is a prevalent blood vessel disorder classified under the broader category of atherosclerosis. Atherosclerosis is a pathological process characterized by the hardening and narrowing of arteries due to the accumulation of atherosclerotic plaques. These plaques are composed of cholesterol, fatty substances, inflammatory cells, calcium, and fibrin, reducing blood flow to...
1.2K
Coronary Artery Disease V: Interprofessional Care01:27

Coronary Artery Disease V: Interprofessional Care

314
Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
314
Acute Coronary Syndrome III: Diagnostic Studies01:30

Acute Coronary Syndrome III: Diagnostic Studies

309
Diagnosing acute coronary syndrome or ACS begins with a thorough patient history. Notable symptoms include central, crushing chest pain radiating to the left arm, neck, jaw, or back, along with shortness of breath, sweating (diaphoresis), nausea, vomiting, dizziness, and palpitations.It is crucial to note any history of cardiac illnesses and assess risk factors, including age, gender, smoking, hypertension, diabetes, hyperlipidemia, and a sedentary lifestyle.During physical examination, vital...
309

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Extraction of Protruding Ostial Stents to Enable Percutaneous Coronary Interventions: The EXPOSE Technique.

JACC. Case reports·2026
Same author

Ten-Year Clinical Outcomes and Cause of Death in Patients on Dialysis Undergoing Percutaneous Coronary Intervention: A Retrospective Mayo Clinic PCI Registry Analysis.

Mayo Clinic proceedings·2026
Same author

Erratum to 'Trends, Predictors, and Outcomes of Temporary Mechanical Circulatory Support for Postcardiac Surgery Cardiogenic Shock' [The American Journal of Cardiology 123(2019) Pages 489-497].

The American journal of cardiology·2026
Same author

Mechanical circulatory support for cardiogenic shock in takotsubo syndrome.

Clinical research in cardiology : official journal of the German Cardiac Society·2026
Same author

Conservative Acute Management of a Large Paradoxical Coronary Embolism: A Case Report and Systematic Literature Review.

JACC. Case reports·2026
Same author

Percutaneous Management of Cabrol Graft Chronic Total Occlusion: Case Report.

Journal of the Society for Cardiovascular Angiography & Interventions·2025

Related Experiment Video

Updated: Feb 18, 2026

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
09:15

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Published on: November 10, 2017

15.1K

Long-term darapladib use does not affect coronary plaque composition assessed using multimodality intravascular

Woong Gil Choi1,2, Megha Prasad1, Ryan Lennon1

  • 1Department of Cardiovascular Diseases.

Coronary Artery Disease
|November 15, 2017
PubMed
Summary

Long-term inhibition of Lipoprotein-associated phospholipase A2 (Lp-PLA2) with darapladib did not alter coronary plaque characteristics. This suggests Lp-PLA2 may not directly impact early atherosclerosis progression in humans.

More Related Videos

In vivo Near Infrared Fluorescence NIRF Intravascular Molecular Imaging of Inflammatory Plaque, a Multimodal Approach to Imaging of Atherosclerosis
09:43

In vivo Near Infrared Fluorescence NIRF Intravascular Molecular Imaging of Inflammatory Plaque, a Multimodal Approach to Imaging of Atherosclerosis

Published on: August 4, 2011

18.6K
Quantification of Atherosclerotic Plaque Activity and Vascular Inflammation using [18-F] Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography FDG-PET/CT
10:02

Quantification of Atherosclerotic Plaque Activity and Vascular Inflammation using [18-F] Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography FDG-PET/CT

Published on: May 2, 2012

18.8K

Related Experiment Videos

Last Updated: Feb 18, 2026

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
09:15

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Published on: November 10, 2017

15.1K
In vivo Near Infrared Fluorescence NIRF Intravascular Molecular Imaging of Inflammatory Plaque, a Multimodal Approach to Imaging of Atherosclerosis
09:43

In vivo Near Infrared Fluorescence NIRF Intravascular Molecular Imaging of Inflammatory Plaque, a Multimodal Approach to Imaging of Atherosclerosis

Published on: August 4, 2011

18.6K
Quantification of Atherosclerotic Plaque Activity and Vascular Inflammation using [18-F] Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography FDG-PET/CT
10:02

Quantification of Atherosclerotic Plaque Activity and Vascular Inflammation using [18-F] Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography FDG-PET/CT

Published on: May 2, 2012

18.8K

Area of Science:

  • Cardiovascular Research
  • Atherosclerosis Imaging

Background:

  • Lipoprotein-associated phospholipase A2 (Lp-PLA2) is implicated in atherosclerotic plaque progression and vulnerability.
  • Coronary endothelial dysfunction is a key factor in early atherosclerosis.

Purpose of the Study:

  • To evaluate the effect of long-term Lp-PLA2 inhibition with darapladib on coronary plaque characteristics.
  • To assess plaque vulnerability indices in patients with endothelial dysfunction using multimodality intravascular imaging.

Main Methods:

  • A double-blinded, randomized study involving 54 patients with suspected ischemia and coronary endothelial dysfunction.
  • Patients received either darapladib or placebo for 6 months.
  • Multimodality intravascular imaging (near-infrared spectroscopy, optical coherence tomography, virtual histology intravascular ultrasound) assessed plaque parameters like maxLCBI4mm, microchannels, macrophages, and necrotic core volume.

Main Results:

  • No significant differences were observed in maximum lipid core burden index (maxLCBI4mm) or macrophage angle between the darapladib and placebo groups.
  • A trend towards shorter microchannel length was noted in the darapladib arm (P=0.08).
  • Percentage of necrotic core volume did not differ significantly between groups.

Conclusions:

  • Six months of darapladib therapy did not significantly change plaque progression or vulnerability indices.
  • The endogenous Lp-PLA2 pathway may not play a direct role in the progression of early human atherosclerosis.
  • Further research may be needed to fully elucidate the role of Lp-PLA2 in cardiovascular disease.